Relevant bibliographies by topics / BRAF mutations

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'BRAF mutations'

Author: Grafiati
Published: 4 June 2021
Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'BRAF mutations.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "BRAF mutations"

1

Menzer, Christian, Alexander M. Menzies, Matteo S. Carlino, et al. "Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations." Journal of Clinical Oncology 37, no. 33 (2019): 3142–51. http://dx.doi.org/10.1200/jco.19.00489.

Full text
Abstract:
PURPOSE BRAF/MEK inhibition is a standard of care for patients with BRAF V600E/K–mutated metastatic melanoma. For patients with less frequent BRAF mutations, however, efficacy data are limited. METHODS In the current study, 103 patients with metastatic melanoma with rare, activating non-V600E/K BRAF mutations that were treated with either a BRAF inhibitor (BRAFi), MEK inhibitor (MEKi), or the combination were included. BRAF mutation, patient and disease characteristics, response, and survival data were analyzed. RESULTS Fifty-eight patient tumors (56%) harbored a non-E/K V600 mutation, 38 (37%
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, Darren, Yazan Abu-Shihab, Deedra Nicolet, et al. "BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML." Blood 144, Supplement 1 (2024): 2921. https://doi.org/10.1182/blood-2024-210110.

Full text
Abstract:
Background: MAPK/RAS signaling pathway mutations are common somatic events in de novo and secondary acute myeloid leukemia (AML), occurring mainly in NRAS, KRAS, and/or PTPN11. BRAF mutations occur with lower frequency in AML and are reported to be universally associated with poor outcome. To date, no comprehensive analysis exists that decisively assesses clinical and molecular characteristics of BRAF-mutated (BRAFm) AML, including insights into clonal architecture, co-occurring mutations, and disease immunophenotype. Methods: We identified 42 AML pts harboring BRAF mutations through targeted
APA, Harvard, Vancouver, ISO, and other styles
3

Xiao, Wenxuan, Ying Liu, Lei Hou, et al. "Retrospective study of BRAF inhibitor-based therapy in patients with BRAF mutated advanced solid tumors (RBAST study)." Journal of Clinical Oncology 42, no. 16_suppl (2024): e23265-e23265. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e23265.

Full text
Abstract:
e23265 Background: BRAF mutations are frequently found in melanoma, non-small cell lung cancer (NSCLC), thyroid cancer, to a lesser degree in other tumor types. These mutations constantly activate the kinase domain and result in MAPK pathway hyperactivation. Successful inhibition of this pathway with BRAF/MEK inhibitors (BRAFi/MEKi) results in a clinically meaningful benefit for some patients. The RBAST study, to assess the efficacy and survival outcomes of BRAF inhibitor-based therapy were investigated in patients with solid tumors harboring BRAF mutations. Methods: Data was collected on a to
APA, Harvard, Vancouver, ISO, and other styles
4

Prophet, Malshundria, Kun Xiao, Theodore Stewart Gourdin, et al. "Detection of actionable BRAF missense mutations by ctDNA-based genomic analysis in prostate cancer." Journal of Clinical Oncology 36, no. 6_suppl (2018): 306. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.306.

Full text
Abstract:
306 Background: Activating BRAF fusion proteins are rare in prostate cancer (PCa) patients. Driver missense BRAF mutations have not been reported in detail in this population. Methods: We examined ctDNA-derived genomic profiles (Guardant 360) from 2,721 unique PCa patients, to identify BRAF genomic anomalies (SNVs, amplification). The ctDNA results were compared with PCa tissue-based genomics from the TCGA database (1,851 unique patients). Results: BRAF missense mutations were found in 76 ctDNA patients (2.8%) and were from all known mutation classes (I, II, III) as well as variants of unknown
APA, Harvard, Vancouver, ISO, and other styles
5

Hwang, Tae Sook, Wook Youn Kim, Hye Seung Han, et al. "Preoperative RAS Mutational Analysis Is of Great Value in Predicting Follicular Variant of Papillary Thyroid Carcinoma." BioMed Research International 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/697068.

Full text
Abstract:
Follicular variant of papillary thyroid carcinoma (FVPTC), particularly the encapsulated subtype, often causes a diagnostic dilemma. We reconfirmed the molecular profiles in a large number of FVPTCs and investigated the efficacy of the preoperative mutational analysis in indeterminate thyroid nodules. BRAF V600E/K601E and RAS mutational analysis was performed on 187 FVPTCs. Of these, 132 (70.6%) had a point mutation in one of the BRAF V600E (n=57), BRAF K601E (n=11), or RAS (n=64) genes. All mutations were mutually exclusive. The most common RAS mutations were at NRAS codon 61. FNA aspirates f
APA, Harvard, Vancouver, ISO, and other styles
6

Stockman, David, Michael T. Tetzlaff, Tariq Al-Zaid, et al. "Differential clinical associations of BRAF and NRAS mutations among histologic types of cutaneous melanomas." Journal of Clinical Oncology 31, no. 15_suppl (2013): e20034-e20034. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20034.

Full text
Abstract:
e20034 Background: Previous studies have investigated whether BRAF and NRAS mutation status in melanoma correlate with histologic parameters and overall survival (OS), but evaluation of mutation groups irrespective of specific mutation among histologic types of melanoma has led to variability in the reproducibility of results. We tested the hypothesis that different histologic types of melanoma (nodular [NM] and superficial spreading [SSM]) have distinct clinical associations with specific BRAF and NRAS mutations. Methods: Primary tumor histology, BRAF/NRAS mutation status, and clinical outcom
APA, Harvard, Vancouver, ISO, and other styles
7

Brinzan, Costel, Mariana Aschie, Catalin Nicolae Grasa, Anca Florentina Mitroi, Elena Matei, and Georgeta Camelia Cozaru. "The Mutation Profiles of KRAS and BRAF Genes in a Romanian Colorectal Cancer Cohort." Revista de Chimie 70, no. 4 (2019): 1346–50. http://dx.doi.org/10.37358/rc.19.4.7124.

Full text
Abstract:
Colorectal cancer (CRC) is one of most commonly diagnosed malignancies and management of CRC differs in according with patient�s characteristics, tumor type, differentiation, metastatic extension and KRAS/BRAF mutations. Based on this knowledge, we examined the relationship between KRAS/BRAF mutations in paraffin-embedded tumor specimens and some clinicopathological features at CRC in order to provide reliable results to the oncologists and so to contribute to the best care provided to the patients. A 56 of colorectal cancer samples were analyzed for the KRAS and BRAF mutational status using S
APA, Harvard, Vancouver, ISO, and other styles
8

Ahn, Hyo Yeong, Chang Hun Lee, Min Ki Lee, et al. "BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients." Medicina 59, no. 6 (2023): 1085. http://dx.doi.org/10.3390/medicina59061085.

Full text
Abstract:
Background and Objectives: BRAF mutational status in resected non-small cell lung cancer (NSCLC) in the Korean population is poorly understood. We explored BRAF (particularly BRAF V600E) mutational status among Korean patients with NSCLC. Materials and Methods: This study included 378 patients with resected primary NSCLC who were enrolled from January 2015 to December 2017. The authors obtained formalin-fixed paraffin-embedded (FFPE) tissue blocks and performed peptide nucleic acid (PNA)-clamping polymerase chain reaction (PCR) for detecting BRAF V600, real-time PCR for detecting BRAF V600E, a
APA, Harvard, Vancouver, ISO, and other styles
9

Zhang, Jianqing, Jiagang Feng, Ling Liu, et al. "Abstract 5774: Investigating the characteristics of BRAF Mutations and its potential relationship with therapy in a large Chinese Lung Cancer cohort." Cancer Research 82, no. 12_Supplement (2022): 5774. http://dx.doi.org/10.1158/1538-7445.am2022-5774.

Full text
Abstract:
Abstract Background: In lung cancer, the proportion of BRAF mutations is low. Rare specific studies have evaluated the BRAF mutation characteristics in lung cancer. Currently, there are some studies suggesting that patients with BRAF mutations may be benefit from immunotherapy, while patients with BRAF V600E may benefit from targeted therapy. Here, the characteristics of BRAF mutation, including BRAF V600E, in a lung cancer cohort of Chinese were analyzed. The characteristics of BRAF mutation with PD-L1 expression were also analyzed. Method: BRAF mutant samples were extracted from 12,051 our c
APA, Harvard, Vancouver, ISO, and other styles
10

Lee, Joon-Hyop, Jiyoung Ahn, Won Seo Park, et al. "Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study." Journal of Clinical Medicine 8, no. 1 (2019): 111. http://dx.doi.org/10.3390/jcm8010111.

Full text
Abstract:
Background: We investigated the associations between v-Raf murine sarcoma viral oncogene homolog B1 (BRAFV600E, henceforth BRAF) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and colorectal cancer (CRC) prognosis, using The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GSE39582) datasets. Materials and Methods: The effects of BRAF and KRAS mutations on overall survival (OS) and disease-free survival (DFS) of CRC were evaluated. Results: The mutational status of BRAF and KRAS genes was not associated with overall survival (OS) or DFS of the CRC patients
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "BRAF mutations"

1

Medina-Pérez, Paula Andrea. "Functional characterization of cancer- and RASopathies-associated SHP2 and BRAF mutations." Doctoral thesis, Humboldt-Universität zu Berlin, Lebenswissenschaftliche Fakultät, 2016. http://dx.doi.org/10.18452/17420.

Full text
Abstract:
Deregulierung des RAS/MAPK Signalwegs führen nicht nur zur Krebsentstehung, sondern sind auch mitverantwortlich für Entwicklungsstörungen, dieals Keimbahnmutationen in Schlüsselregulatoren des MAPK Signalwegs zurückzuführen sind, werden aufgrund überlappender Phänotypen unter dem Begriff RASopathien subsumiert. Obwohl die Inzidenz für solide Tumore bei diesen Patienten gering ist, wird ein Zusammenhang zum Auftreten verschiedener Leukämieformen deutlich. Im Rahmen dieser Arbeit wurden Mutationen zweier Schlüsselregulatoren des MAPK Signalwegs, PTPN11 und BRAF, hinsichtlich ihrer Fähigkeit zur
APA, Harvard, Vancouver, ISO, and other styles
2

Ali, Muhammad Akhtar. "Understanding Cancer Mutations by Genome Editing." Doctoral thesis, Uppsala universitet, Genomik, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-235680.

Full text
Abstract:
Mutational analyses of cancer genomes have identified novel candidate cancer genes with hitherto unknown function in cancer. To enable phenotyping of mutations in such genes, we have developed a scalable technology for gene knock-in and knock-out in human somatic cells based on recombination-mediated construct generation and a computational tool to design gene targeting constructs. Using this technology, we have generated somatic cell knock-outs of the putative cancer genes ZBED6 and DIP2C in human colorectal cancer cells. In ZBED6-/- cells complete loss of functional ZBED6 was validated and l
APA, Harvard, Vancouver, ISO, and other styles
3

Seitz-Alghrouz, Ruth Christin [Verfasser], and Paul [Akademischer Betreuer] Fisch. "BRAF V600E mutations in nevi and melanocytic tumors of uncertain malignant potential (MELTUMPs)." Freiburg : Universität, 2019. http://d-nb.info/1188195891/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cesari, Valentina <1985&gt. "High sensitivity analysis of BRAF mutations in neoplastic and non-neoplastic thyroid lesions." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2014. http://amsdottorato.unibo.it/6360/1/Cesari_Valentina_tesi.pdf.

Full text
Abstract:
The clonal distribution of BRAFV600E in papillary thyroid carcinoma (PTC) has been recently debated. No information is currently available about precursor lesions of PTCs. My first aim was to establish whether the BRAFV600E mutation occurs as a subclonal event in PTCs. My second aim was to screen BRAF mutations in histologically benign tissue of cases with BRAFV600E or BRAFwt PTCs in order to identify putative precursor lesions of PTCs. Highly sensitive semi-quantitative methods were used: Allele Specific LNA quantitative PCR (ASLNAqPCR) and 454 Next-Generation Sequencing (NGS). For the firs
APA, Harvard, Vancouver, ISO, and other styles
5

Cesari, Valentina <1985&gt. "High sensitivity analysis of BRAF mutations in neoplastic and non-neoplastic thyroid lesions." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2014. http://amsdottorato.unibo.it/6360/.

Full text
Abstract:
The clonal distribution of BRAFV600E in papillary thyroid carcinoma (PTC) has been recently debated. No information is currently available about precursor lesions of PTCs. My first aim was to establish whether the BRAFV600E mutation occurs as a subclonal event in PTCs. My second aim was to screen BRAF mutations in histologically benign tissue of cases with BRAFV600E or BRAFwt PTCs in order to identify putative precursor lesions of PTCs. Highly sensitive semi-quantitative methods were used: Allele Specific LNA quantitative PCR (ASLNAqPCR) and 454 Next-Generation Sequencing (NGS). For the firs
APA, Harvard, Vancouver, ISO, and other styles
6

SPAGNOLETTI, GIROLAMO. "Molecular mechanisms responsible for radiation resistance in colonrectal tumors." Doctoral thesis, Università di Foggia, 2016. http://hdl.handle.net/11369/339024.

Full text
Abstract:
Abstract Introduction Radiotherapy is a well-established therapeutic modality for cancer. It is considered a crucial treatment for most common types of cancer and is usually used in conjunction with chemotherapy, hormone therapy or surgery. However, the presence of radioresistant cells is one of the major obstacles to successful treatment with radiotherapy. Ionizing radiation exerts its cytotoxic effect by the induction of double strand breaks (DSBs) and non-DSB highly clustered DNA lesions consisting in a combination of single strand breaks (SSBs), abasic sites and oxidized bases within
APA, Harvard, Vancouver, ISO, and other styles
7

Novo, Sonia Marisa. "Use of an ex vivo model of human colorectal tumours to study response to the MEK1/2 inhibitor AZD6244." Thesis, University of Edinburgh, 2013. http://hdl.handle.net/1842/11778.

Full text
Abstract:
Colorectal cancer is the second most common cause of cancer death in Western Europe and North America. Current therapies are largely ineffective and are associated with considerable morbidity. Activating mutations in KRAS and BRAF genes are frequent in colorectal cancer, especially at later stages of the disease, and result in constitutive activity of the MAPK pathway, leading to increased proliferation and tumour survival. The MEK1/2 inhibitor AZD6244, that targets the MAPK pathway downstream of these mutations, has been tested as novel therapy for colorectal cancer. However, clinical trials
APA, Harvard, Vancouver, ISO, and other styles
8

Figueroa, Vazquez Vianihuini [Verfasser], and Marc-Steffen [Akademischer Betreuer] Raab. "Functional characterizations of BRAF mutations in multiple myeloma / Vianihuini Figueroa Vazquez ; Betreuer: Marc-Steffen Raab." Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://d-nb.info/1178010937/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Medina-Pérez, Paula Andrea [Verfasser], Reinhold [Akademischer Betreuer] Schäfer, Hanspeter [Akademischer Betreuer] Herzel, and Holger [Akademischer Betreuer] Sültmann. "Functional characterization of cancer- and RASopathies-associated SHP2 and BRAF mutations / Paula Andrea Medina-Pérez. Gutachter: Reinhold Schäfer ; Hanspeter Herzel ; Holger Sültmann." Berlin : Lebenswissenschaftliche Fakultät, 2016. http://d-nb.info/1081980923/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Moulière, Florent. "Etude de la structure et de l'origine des ADN circulants : application à la mise au point d'un test de détection des mutations KRAS et BRAF dans le cancer colorectal." Thesis, Montpellier 2, 2012. http://www.theses.fr/2012MON20245/document.

Full text
Abstract:
Les ADN circulants extracellulaires (ADNcf) sont considérés comme des biomarqueurs potentiels non invasifs de la progression tumorale. Ils présentent l'avantage d'être porteurs des altérations génétiques des tumeurs dont ils sont issus. Les connaissances sur les formes, les mécanismes de libération et les actions biologiques des ADNcf sont cependant encore peu caractérisées.Nous avons émis l'hypothèse que se focaliser sur l'étude de la structure et des origines des ADNcf issus des tumeurs permettrait d'ouvrir de nouvelles perspectives d'applications en génomique personnalisée.Nos travaux ont d
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "BRAF mutations"

1

Smith, Robert A., and Alfred K. Lam. "BRAF Mutations in Papillary Thyroid Carcinoma: A Genomic Approach Using Probe-Based DNA Capture for Next-Generation Sequencing." In Methods in Molecular Biology. Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2505-7_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pedone, Katherine H., Jennifer L. Sells, and Channing J. Der. "Mutational Activation of KRAS and BRAF in Colorectal Cancer." In Molecular Pathogenesis of Colorectal Cancer. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-8412-7_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Verdelho, Maria R., Simão Gonçalves, Luisa Gonçalves, et al. "Predictive Biomarkers in Melanoma: Detection of BRAF Mutation Using Dermoscopy." In Artificial Intelligence over Infrared Images for Medical Applications and Medical Image Assisted Biomarker Discovery. Springer Nature Switzerland, 2022. http://dx.doi.org/10.1007/978-3-031-19660-7_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Verdelho, Maria R., Simão Gonçalves, Luisa Gonçalves, et al. "Correction to: Predictive Biomarkers in Melanoma: Detection of BRAF Mutation Using Dermoscopy." In Artificial Intelligence over Infrared Images for Medical Applications and Medical Image Assisted Biomarker Discovery. Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-19660-7_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Schönleben, Frank, W. Qiu, W. Hohenberger, and G. H. Su. "PIK3CA, KRAS und BRAF Mutationen in Intraduktalen Papillären Muzinösen Neoplasien/Karzinomen (IPMN/C) des Pankreas." In Chirurgisches Forum 2008. Springer Berlin Heidelberg, 2008. http://dx.doi.org/10.1007/978-3-540-78833-1_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

de Oliveira Cavagna, Rodrigo, Leticia Ferro Leal, Flávia Escremim de Paula, Gustavo Noriz Bernardinelli, and Rui Manuel Reis. "A PCR-Based Approach for Driver Mutation Analysis of EGFR, KRAS, and BRAF Genes in Lung Cancer Tissue Sections." In Methods in Molecular Biology. Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1278-1_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"BRAF Mutations." In Diagnostic Pathology: Molecular Oncology. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-37678-5.50045-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pulica, Rachael, Karine Cohen Solal, and Ahmed Lasfar. "Role of RUNX2 in Melanoma: A New Player in Tumor Progression and Resistance to Therapy." In Melanoma. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.97105.

Full text
Abstract:
RUNX2, a transcription factor, initially known for its indispensable role in skeletal development. RUNX2 is essential for osteoblast differentiation and the maintain of the osteocyte balance. RUNX2 acts directly on osteoblasts via Fgf pathway or on mesenchymal progenitors through Hedgehog, Wnt, Pthlh and DLX5. Currently, many reports point its critical role in the progression and metastasis of several cancer types. RUNX2 is involved in EMT process, invasion and metastasis through the modulation of important oncogenic pathways, including Wnt, FAK/PTK and AKT. In melanoma, RUNX2 is a key player
APA, Harvard, Vancouver, ISO, and other styles
9

Wooster, Richard, Andrew P. Futreal, and Michael R. Stratton. "Sequencing Analysis of BRAF Mutations in Human Cancers." In Regulators and Effectors of Small GTPases: Ras Family. Elsevier, 2006. http://dx.doi.org/10.1016/s0076-6879(05)07018-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bogenrieder Thomas and Herlyn Meenhard. "The molecular pathology of cutaneous melanoma." In Translational Pathology of Early Cancer. IOS Press, 2012. https://doi.org/10.3233/978-1-61499-024-6-267.

Full text
Abstract:
Cutaneous melanoma is a highly aggressive cancer with still limited, but increasingly efficacious, standard treatment options. Recent preclinical and clinical findings support the notion that cutaneous melanoma is not one malignant disorder but rather a family of distinct molecular diseases. Incorporation of genetic signatures into the conventional histopathological classification of melanoma already has great implications for the management of cutaneous melanoma. Herein, we review our rapidly growing understanding of the molecular biology of cutaneous melanoma, including the pathogenic roles
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "BRAF mutations"

1

Hernández-Pérez, Carlos, Lauren Jimenez-Martin, and Veronica Vilaplana. "Bridging Domains in Melanoma Diagnostics: Predicting BRAF Mutations and Sentinel Lymph Node Positivity with Attention-Based Models in Histological Images." In 2024 IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops (CVPRW). IEEE, 2024. http://dx.doi.org/10.1109/cvprw63382.2024.00520.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yapeter, Calista Adele, Katerina-Theresa Mantikas, Costanza Gulli, et al. "Electrochemical Sensing of the Colorectal Cancer BRAF p.V600E Mutation Using a Lab-on-Chip Integrated DNA Amplification Analysis Method." In 2024 IEEE SENSORS. IEEE, 2024. https://doi.org/10.1109/sensors60989.2024.10784606.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Abubekerov, S. K., A. V. Kornilov, and I. A. Tyurina. "ASSESSMENT OF THE EFFECT OF THE MICROBIOME ON THE DEVELOPMENT OF COLORECTAL CANCER AFTER SURGERY ON THE GASTROINTESTINAL TRACT." In Scientific research of the SCO countries: synergy and integration. Crossref, 2024. http://dx.doi.org/10.34660/inf.2024.38.71.003.

Full text
Abstract:
We studied the influence of the microbiome on the development of colorectal cancer (CRC) after surgical interventions on the gastrointestinal tract (GIT) (appendectomy, cholecystectomy, polypectomy). 381 patients were analyzed; variables such as CRC mutational activity (KRAS, BRAF, MSI, NRAS, HER2) were included in the study. The analysis showed a high frequency of BRAF mutations in patients with a previous appendectomy, 4.8 times compared to the control group. We associate the obtained data with the influence of Fusobacterium nucleatum on the development of colorectal cancer, the role of whic
APA, Harvard, Vancouver, ISO, and other styles
4

Chui, M. Herman, and Ie-Ming Shih. "Abstract B21: Oncogenic BRAF and KRAS mutations in endosalpingiosis." In Abstracts: AACR Special Conference on Advances in Ovarian Cancer Research; September 13-16, 2019; Atlanta, GA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.ovca19-b21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Barbash, Zohar, Dikla Haham, Liat Hafzadi, et al. "Abstract 1092: A systematic analysis of BRAF mutations and their sensitivity to different BRAF inhibitors." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-1092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Taylor-Weiner, Amaro N., Priscilla K. Brastianos, Peter E. Manley, et al. "Abstract 935: Exome sequencing reveals BRAF mutations in papillary craniopharyngiomas." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-935.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sen, Banibrata, Shaohua Peng, Ximing Tang, et al. "Abstract 3667: Inactivating BRAF mutations confer dasatinib sensitivity in lung cancer." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3667.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lu, Li-Chun, Yu-Yun Shao, Min-Shu Hsieh, Chien-Chung Huang, Ann-Lii Cheng та Chih-Hung Hsu. "Abstract 4584: β-catenin (CTNNB1) and BRAF mutations in advanced hepatocellular carcinoma". У Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4584.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gopal, Priyanka, Elif I. Sarihan, and Mohamed E. Abazeed. "Abstract 2194: Subclonal variation and evolutionary dynamics of BRAF mutations in cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2194.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Johnson, Faye, Banibrata Sen, Tuhina Mazumdar, et al. "Abstract IA10: Kinase-impaired BRAF mutations as predictors of resistance and sensitivity." In Abstracts: AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy; June 18-21, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.pms14-ia10.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "BRAF mutations"

1

Toraih, Eman, Alyssa Webster, Rami Elshazli, et al. The Prevalence and Prognostic Implications of BRAF K601E Mutations in Thyroid Neoplasms: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.9.0003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ragunathan, Yoithapprabhunath Thuckanaickenpalayam, Srichinthu Kenniyan Kumar, Deepak Gupta, Diksha Singh, Swetha Pasupuleti, and Madhavan Nirmal Ramdas. Effectiveness of Neoadjuvant Molecular-Targeted Chemotherapy in Ameloblastoma - A Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.6.0018.

Full text
Abstract:
Review question / Objective: The aim of this article is to obtain an in-depth review of ameloblastoma tumor to determine the available level of evidence and the possible benefit of targeted therapeutics for the treatment of BRAF V600E mutation in ameloblastoma tumor. Condition being studied: Ameloblastoma is an epithelium-derived odontogenic tumour that evolved since the prehistoric era. Ameloblastoma is unique among the odontogenic neoplasms occurring in the jaws, because of its locally invasive behaviour and high recurrence rate. Facial asymmetry, displacement of teeth, malocclusion, and pat
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'BRAF mutations' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography